J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 6, Number 4, August 2014, pages 252-260

Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy

Figure

Figure 1. The doses of VCR (A), adriamycin (B), cyclophosphamide (C) and prednisolone (D) in the early-onset VIPN (-) group (n = 27) and the early-onset VIPN (+) group (n = 14). ADR: adriamycin; CPA: cyclophosphamide; PSL: prednisolone.

Tables

**Table 1.** Characteristics of the Study Population of 41 Patients Treated With an R-CHOP or R-CHOP-Like Regimen for the First Time
Factor	Early-onset VIPN (-) (n = 27)	Early-onset VIPN (+) (n = 14)	P value
Factor	Means ± SD or no. of patients (%)	Means ± SD or no. of patients (%)	P value
^aFisher’s exact probability test. ^bMann-Whitney U test. ^cStudent’s t-test.
Peripheral neuropathy
Grade 1		11 (79)
Grade 2		2 (14)
Grade 3		1 (7)
Grade 4		0 (0)
Gender (male/female)	16/11	5/9	0.20^a
Age, median (range) (years)	68 (41 - 87)	53 (34 - 72)	0.0064^b
Body weight	59.9 ± 10.4	56.2 ± 11.3	0.31^c
Aspartate aminotransferase	28.9 ± 12.4	22.0 ± 11.6	0.59^c
Alanine aminotransferase	15.5 ± 8.1	25.3 ± 13.7	0.12^c
γ-glutamyl transpeptidase	33.8 ± 24.9	48.5 ± 34.7	0.57^c
Total bilirubin	0.60 ± 0.24	0.67 ± 0.24	0.37^c
Creatinine clearance	97.9 ± 40.3	112.9 ± 18.5	0.20^c
Diabetes mellitus requiring medication	4 (15)	1 (7)	0.66^a
Lymphoma type
Diffuse large B-cell lymphoma	15 (56)	9 (64)	0.74^a
Follicular lymphoma	7 (26)	2 (14)	0.70^a
Others	5 (18)	3 (22)	1.00^a
Regimen
Normal-dose chemotherapy	17 (63)	14 (100)	0.0085^a
R-CHOP	14 (52)	12 (86)	0.044^a
R-CVP	3 (11)	2 (14)	1.00^a
Reduced-dose chemotherapy
R-THP-COP	10 (37)	0 (0)	0.0085^a
Concomitant use of aprepitant	9 (33)	10 (71)	0.026^a

**Table 5.** Risk Factors for Developing Early-Onset VIPN by Multivariate Logistic Regression Analysis
Factor	Odds ratio	95% CI	P value
Age ≥ 65 years	0.90	0.13 - 6.38	0.92
VCR dose ≥ 1.9 mg	15.29	1.14 - 205.66	0.039
Concomitant use of aprepitant	6.09	1.15 - 32.11	0.033